Anti-neurofascin demyelinating diseases

Anti-neurofascin demyelinating diseases (anti-NF diseases) refers to health conditions engendered by auto-antibodies against neurofascins, which can produce both central and peripheral demyelination. Some cases of combined central and peripheral demyelination (CCPD) could be produced by them.[1]

  • Chronic inflammatory demyelinating polyneuropathy: Some cases of CIDP are reported to be produced by auto-antibodies against several neurofascin proteins. These proteins are present in the neurons and four of them have been reported to produce disease: NF186, NF180, NF166 and NF155.[2]
  • Neuromyelitis optica: NF auto antibodies can also appear in NMO cases.[2] These antibodies are more related to the peripheral nervous demyelination, but they were also found in NMO.[3]
  • Multiple sclerosis: Also antibodies against Neurofascins NF-155 can also appear in atypical multiple sclerosis[4] and NF-186 could be involved in subtypes of MS[5] yielding an intersection between both conditions. Around 10% of MS cases are now thought to be anti-NF cases.[6][7]

History

The first report about a subgroup of MS patients with anti-NF and contactin 2 auto-antibodies was published in 2011[8]

References

  1. ↑ J. Ciron et al. The coexistence of recurrent cerebral tumefactive demyelinating lesions with longitudinally extensive transverse myelitis and demyelinating neuropathy, Multiple Sclerosis and Related Disorders, Volume 27, January 2019, Pages 223-225
  2. 1 2 Jun-ichi Kira, Ryo Yamasaki, Hidenori Ogata, Anti-neurofascin autoantibody and demyelination, Neurochemistry international, Dec. 2018, doi: https://doi.org/10.1016/j.neuint.2018.12.011
  3. ↑ Kun Jia et al., Anti-neurofascin-155 antibody-positive neuromyelitis optica spectrum disorders, Journal of Neurological Sciences, January 16, 2019, DOI: https://doi.org/10.1016/j.jns.2019.01.024
  4. ↑ Stich O, Perera S, Berger B, Jarius S, Wildemann B, Baumgartner A, Rauer S (March 2016). "Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis". Journal of the Neurological Sciences. 364: 29–32. doi:10.1016/j.jns.2016.03.004. PMID 27084211.
  5. ↑ Early research into a treatment for progressive MS
  6. ↑ Marcus Vinicius, Magno Goncalves, Yara Dadalti Fragoso, The involvement of anti-neurofascin 155 antibodies in central and peripheral demyelinating diseases, Neuroimmunol Neuroinflammation, 8 Apr 2019;6:6.10.20517/2347-8659.2019.08
  7. ↑ Nobutoshi Kawamura, Ryo Yamasaki, Tomomi Yonekawa, Takuya Matsushita, Susumu Kusunoki, Shigemi Nagayama, Yasuo Fukuda, Hidenori Ogata, Dai Matsuse, Hiroyuki Murai, Jun-ichi Kira, Anti-neurofascin antibody in patients with combined central and peripheral demyelination, July 24, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182a1aa9c
  8. ↑ Edgar Meinl, Tobias Derfuss, Markus Krumbholz, Anne-Katrin Pröbstel, Reinhard Hohlfeld, Humoral autoimmunity in multiple sclerosis, Journal of the Neurological Sciences, Volume 306, Issues 1–2, 15 July 2011, Pages 180-182, https://doi.org/10.1016/j.jns.2010.08.009
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.